TeamDrive
RUS

Russia approves new state strategy for pharmaceutical industry

19 September 2018

GMP News

A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

At the heart of the new strategy is increasing the domestic production of innovative drugs and the beginning of their massive exports to abroad, primarily to emerging nations of Asia-Pacific, Latin America and Eastern Europe, reports The Pharma Letter’s local correspondent.

According to an official spokesman for Russian Minister of Health Veronika Skvorstsova, in recent years the quality of domestically-produced drugs has significantly improved, while the range has become more diversified. At the same time, in addition to common drugs, the production of vaccines has also increased.

According to Ms Skvortsova’s spokesman, drug exports out of Russia are also being considered by some global pharmaceutical companies operating production facilities within Russia.

Due to the devaluation of the Russian currency – the rouble - that has been observed in recent years, drug exports out of Russia has become more profitable to producers than supplies to the domestic market.

Finally, the new strategy involves the production of active substances in Russia which, in turn, should create conditions for the establishment of drug production, starting from zero.

Source


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more